S-2 (Rathburn) / water analytical gradient with 0.1% formic acid at a flow rate of 0.4 mL/min. Eluted proteins were directly introduced to a Bruker MicrOTOF II mass spectrometer (Bruker Daltonics) via an ESI source. MS mode: ES+. Scan range (m/z): 625-3000. Data obtained in continuum mode. The electrospray source of the MS was operated with a capillary voltage of 4.5 kV and a capillary exit voltage of 160 V. Nitrogen was used as the nebulizer and dry gas at a 3.0 bar pressure for the nebulizer gas and 7.0 L/min for the dry gas. Ion series were generated by integration of the total ion chromatogram (TIC) over the 1.5-2.0 min range. Total mass spectra for protein samples were reconstructed from the ion series using the Compass DataAnalysis software using a baseline subtraction of 0.4 and a Gaussian smoothing with a width of 0.076 Da before deconvolution. All instrument control and sample tables were controlled using BioPharma Compass™ (Bruker Daltonics).
Protein LC-MS (for Figures S18-S19)
LC-MS was performed on protein samples using a Thermo Scientific uPLC connected to MSQ Plus Single Quad Detector (SQD). Column: Hypersil Gold C4, 1.9 μm, 2.1 × 50 mm. Wavelength: 254 nm. Mobile Phase: 99:1 Water (0.1% formic acid): MeCN (0.1% formic acid) to 1:9 Water (0.1% formic acid): MeCN (0.1% formic acid) gradient over 4.5 min. Flow Rate: 0.3 mL/min. MS Mode: ES+. Scan Range: m/z = 500-2000. Scan time: 1.5 s. Data obtained in continuum mode. The electrospray source of the MS was operated with a capillary voltage of 3.5 kV and a cone voltage of 50 V. Nitrogen was used as the nebulizer and desolvation gas at a total flow of 600 L/h. Ion series were generated by integration of the total ion chromatogram (TIC) over the 3.3-3.8 min range. Total mass spectra for protein samples were reconstructed from the ion series using the pre-installed ProMass software using default settings for large proteins in m/z range 500-1500.
S-3
Cloning and expression of proteins 
S-4
Synthesis of compounds 3-Bromo-1-methyl-1H-pyrrole-2,5-dione 1 To a solution of N-methylmaleimide (2.87 g, 25.0 mmol) in CHCl 3 (125 mL) was added bromine (2.60 mL, 55.5 mmol) dropwise and the resulting mixture was refluxed for 2 h. After this time, the solvent was removed in vacuo and the resulting solid dissolved in EtOAc (30 mL) and washed with 15% aq. Na 2 S 2 O 3 (20 mL). The product was extracted with EtOAc (3 x 30 mL), dried (MgSO 4 ) and the solvent was removed in vacuo to afford crude 2,3-dibromosuccinimide as yellow crystals. The succinimide product was dissolved in AcOH (150 mL), to which was added sodium acetate (5.94 g, 71.6 mmol) and the reaction mixture was refluxed for 2.5 h. After this time, the reaction mixture was left to cool down to room temperature before the solvent was removed in vacuo. The crude mixture was dissolved in EtOAc (50 mL) and washed with sat. aq. Na 2 CO 3 (3 x 25 mL). 
S-9
Attempted hydrolysis of succinimide bioconjugate 2
Hydrolysis was carried out by adding glycine (250 mM stock) to N-methyl succinimide albumin conjugate 2 (25 mM final concentration), adjusting the pH to pH 9 with 0.5 M NaOH and incubating overnight at 37 °C. The resulting conjugate was placed in fresh PBS (pH 7.4) using a PD MidiTrap G-25 (GE Healthcare) following the manufacturer's instructions. The sample was analysed by GPC for concentration and LC-MS. Intens. 64500 65000 65500 66000 66500 67000 67500 68000 68500 69000 m/z
S-11
Reaction of human serum albumin with 3-bromo-1-methyl-1H-pyrrole-2,5-dione
As >90% of cysteine-34 of albumin is in its reduced form, no pre-treatment was necessary. To albumin 1 (900 µL, 209 µM, 188 nmol) in PBS (pH 7.4) was added a freshly prepared solution of 3-bromo-1-methyl-1H-pyrrole-2,5-dione (100 µL, 2.82 mM, 282 nmol) in PBS (pH 7.4), and the reaction mixture incubated at room temperature in the dark for 3 hours. The reaction was desalted using a PD MidiTrap G-25 (GE Healthcare) following the manufacturer's instructions. The sample was analysed by GPC for concentration and LC-MS. Expected mass: 66,548 Da (bioconjugate 4). Observed mass: 66,548 Da. Intens. 63000 64000 65000 66000 67000 68000 69000 70000
S-19

Stability experiment with bioconjugate 5 in PBS with Thiol
Bioconjugate 5 (53 μL, 37.6 μM, 2 nmol) was diluted to a final concentration of 20 μM by adding PBS (pH 7.4) (37 μL) and a solution of GluSH (10 μL, 10 mM, 100 nmol) in PBS (pH 7.4) to give a 50 times excess of GluSH to albumin. This sample was placed at 37 °C protected from light. The sample was analysed by LC-MS at different times. Bioconjugate 2 (53 μL, 37.6 μM, 2.00 nmol) was diluted to a final concentration of 20 μM by adding PBS (pH 7.4) (37 μL) and a solution of GluSH (10 μL, 10 mM, 100 nmol) in PBS (pH 7.4) to give a 50 times excess of GluSH to albumin. This sample was placed at 37 °C protected from light. Intens. 65000 65500 66000 66500 67000 67500 68000 68500 m/z
S-31
Reaction of human serum albumin with Alexafluor bromomaleimide 2-(6-Amino-3-iminio-4,5-disulfonato-3,10-dihydroanthracen-9-yl)-5-((5-(4-((3-bromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)pentyl) carbamoyl) benzoate (Alexafluro bromomaleimide) was prepared by reaction of 3-bromo-1-(prop-2-yn-1-yl)-1H-pyrrole-2,5-dione and Alexa Fluor® 488 azide, conditions as reported by Machida et al. 2 using CuBr in place of CuI and THPTA in place of TBTA: 2 THPTA (3.3 μL, 40 mM in dry DMF) was added to a solution of CuBr (3.3 μL, 40 mM in dry acetonitrile). 3-Bromo-1-(prop-2-yn-1-yl)-1H-pyrrole-2,5-dione (6.5 μL, 10 mM in dry acetonitrile) was added to the premixed copper solution. Alexa Fluor 488 azide (7.5 μL, 10 mM in dry DMF) was added to the reaction mixture and left under argon overnight at room temperature.
To albumin 1 (50 µL, 100 µM, 5 nmol) in PBS (pH 7.4) was added a freshly prepared solution of 2-(6-amino-3-iminio-4,5-disulfonato-3,10-dihydroanthracen-9-yl)-5-((5-(4-((3-bromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)pentyl) carbamoyl) benzoate (5 µL, 2.5 mM, 12.5 nmol) in PBS (pH 7.4), and the reaction mixture incubated at room temperature for 1 h. The small molecules were removed by ultrafiltration using a Vivaspin 500 (MWCO 5,000 Generon). Conjugate 6 was characterized by LC-MS and purity checked by SEC-HPLC (220 nm). Expected mass: 67,230 Da (bioconjugate 6).
Observed mass: 67,204 Da. UV-Vis absorption spectrum of the conjugate gave a fluorophore to albumin ratio of 1.03:1. To promote hydrolysis of the bridging agent, conjugate 6 was buffer swapped into borate buffer (0.1 M, 1 mM EDTA, pH 9) and incubated for 24 h at 37 °C. An aliquot (5 µL) was diluted four times with water and analysed by LC-MS. Observed masses: 67,221 Da. Expected mass: 67,248 Da. UV-Vis absorption spectrum of the conjugate gave a fluorophore to albumin ratio of 1.02:1. 
